Dublin, June 28, 2019 (GLOBE NEWSWIRE) -- The "Global Uveitis Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Several risk factors associated with uveitis had been a challenge during the diagnosis of eye disorders. Considering the complexities related to the diagnosis, vendors in the market are developing novel diagnostic tools and methods to treat patients with uveitis.

Several companies are introducing AI-implemented medical devices to detect the level of diabetic retinopathy in patients with diabetes. Devices integrated with AI work autonomously and eliminate the need for specialists to make clinical decisions. Many such advancements have made the diagnosis of eye conditions easier.

Ophthalmologists are leveraging such technical advantages and are providing the right treatment to patients. This is expected to drive the growth of the global uveitis drugs market size at a CAGR of around 7% during 2019-2023.

High prevalence of eye disorders and associated risk factors of uveitis

Uveitis is associated with several inflammatory diseases that cause swelling and destroy eye tissues. People with AIDS, rheumatic arthritis, multiple sclerosis, TB, and syphilis are more vulnerable to eye-related risk factors. The high prevalence of these diseases will have a positive impact on the market's growth.

Availability of substitutes

Despite the availability of approved drugs, healthcare practitioners are adopting alternative treatment options such as surgery, laser treatment, and biopsy due to the side-effects associated with uveitis drugs. This is expected to hinder the growth of the global uveitis drugs market during the forecast period.

Competitive Landscape

The market appears to be fragmented with several players occupying the market share. Companies such as AbbVie and Allergan have intensified competition. Factors such as the recent advancements in the diagnosis of eye disorders and the high prevalence of eye disorders and associated risk factors of uveitis will provide significant growth opportunities for uveitis drug companies.

Key Players

• AbbVie Inc.
• Allergan PLC
• Johnson & Johnson Services Inc.
• Novartis AG
• Pfizer Inc.

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

• Comparison by product
• Small molecules - Market size and forecast 2018-2023
• Biologics - Market size and forecast 2018-2023
• Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• RoW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

• Development of gene therapy
• Special designations
• Increasing popularity of combination therapies

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie Inc.
• Allergan PLC
• Johnson & Johnson Services Inc.
• Novartis AG
• Pfizer Inc.

For more information about this report visit https://www.researchandmarkets.com/r/13rq5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Optical Disorders Drugs

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.